Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peperidone hydrochloride
- Development stage
- Unknown
- Lead developer
- Guangzhou Zhongwei Biotechnology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Peperidone hydrochloride (also known as piperphentonamine hydrochloride or Jiaobentong'an hydrochloride) is a novel small molecule cardiotonic agent developed by Guangzhou Zhongwei Biotechnology for the treatment of heart failure. It functions as a pure calcium sensitizer by increasing the sensitivity of cardiac troponin C to calcium ions, thereby enhancing myocardial contractility (positive inotropy) without increasing intracellular calcium levels or myocardial oxygen consumption. Unlike other inodilators such as levosimendan, peperidone hydrochloride does not inhibit phosphodiesterase 3 (PDE3) or increase cyclic AMP (cAMP) levels, which may reduce the risk of arrhythmias and other cAMP-mediated adverse effects. In addition to its inotropic effects, it exhibits vasodilating and cardioprotective properties, particularly against ischemia-reperfusion injury. The drug has been evaluated in Phase II clinical trials in China for hospitalized patients with acute or chronic heart failure requiring inotropic support.
- Other names
- peridone hydrochloridepiperphentonamine盐酸椒苯酮胺
02
Targets
TNC (Tenascin-C fibronectin type III domains)
Beyond the preview
Go deeper on peperidone hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peperidone hydrochloride.